Company news
Lyell Immunopharma, Inc. (NASDAQ:LYEL) news
Every Lyell Immunopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
September 14, 2026
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal ...
September 10, 2026
Lyell Immunopharma : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
August 6, 2026
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 25, 2026
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Lar...
June 12, 2026
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 ...
June 8, 2026
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology A...
June 4, 2026
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 1, 2026
Lyell Immunopharma Announces Participation in May Investor Conferences
May 12, 2026
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
May 6, 2026
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
March 12, 2026
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chie...
March 9, 2026
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chie...
March 9, 2026
Lyell Immunopharma Announces Participation in March Investor Conferences
February 23, 2026
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressi...
February 12, 2026
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patient...
December 7, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 12, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 12, 2025
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metasta...
November 10, 2025
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lympho...
November 3, 2025
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lympho...
September 3, 2025
Lyell Immunopharma Announces Participation in September Investor Conferences
September 2, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
August 12, 2025
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
July 25, 2025
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
June 23, 2025
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial o...
June 17, 2025
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
June 9, 2025
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
June 4, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
May 13, 2025
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell ...
May 1, 2025
Novavax Appoints Charles Newton to Board of Directors
April 29, 2025
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Ref...
April 15, 2025
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
March 11, 2025
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
February 18, 2025
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
January 9, 2025
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2...
December 9, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
November 7, 2024
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma ...
November 5, 2024
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
October 31, 2024
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
October 24, 2024
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 4, 2024
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
September 24, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
August 7, 2024
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate En...
June 26, 2024
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
May 7, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
May 6, 2024
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
March 5, 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
February 28, 2024